AU2009279771B2 - Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine - Google Patents

Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine Download PDF

Info

Publication number
AU2009279771B2
AU2009279771B2 AU2009279771A AU2009279771A AU2009279771B2 AU 2009279771 B2 AU2009279771 B2 AU 2009279771B2 AU 2009279771 A AU2009279771 A AU 2009279771A AU 2009279771 A AU2009279771 A AU 2009279771A AU 2009279771 B2 AU2009279771 B2 AU 2009279771B2
Authority
AU
Australia
Prior art keywords
capecitabine
compound
hki
manufactured
ski
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009279771A
Other languages
English (en)
Other versions
AU2009279771A1 (en
Inventor
Florence Binlich
Susan Quinn
Kenneth Wang
Charles Zacharchuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009279771(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2009279771A1 publication Critical patent/AU2009279771A1/en
Application granted granted Critical
Publication of AU2009279771B2 publication Critical patent/AU2009279771B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009279771A 2008-08-04 2009-08-04 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine Active AU2009279771B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8591308P 2008-08-04 2008-08-04
US61/085,913 2008-08-04
US17246609P 2009-04-24 2009-04-24
US61/172,466 2009-04-24
PCT/US2009/052644 WO2010017163A1 (en) 2008-08-04 2009-08-04 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine

Publications (2)

Publication Number Publication Date
AU2009279771A1 AU2009279771A1 (en) 2010-02-11
AU2009279771B2 true AU2009279771B2 (en) 2015-05-14

Family

ID=41226678

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009279771A Active AU2009279771B2 (en) 2008-08-04 2009-08-04 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine

Country Status (26)

Country Link
US (2) US8669273B2 (enExample)
EP (3) EP3175853B1 (enExample)
JP (1) JP5681108B2 (enExample)
KR (2) KR101434009B1 (enExample)
CN (6) CN105963313A (enExample)
AU (1) AU2009279771B2 (enExample)
BR (1) BRPI0916694B1 (enExample)
CA (1) CA2730715C (enExample)
CY (1) CY1118602T1 (enExample)
DK (1) DK2326329T3 (enExample)
ES (2) ES2968373T3 (enExample)
HK (1) HK1218262A1 (enExample)
HR (1) HRP20170074T1 (enExample)
HU (1) HUE032958T2 (enExample)
IL (1) IL210616A (enExample)
LT (1) LT2326329T (enExample)
MX (1) MX2011001318A (enExample)
NZ (1) NZ590464A (enExample)
PL (2) PL2326329T3 (enExample)
PT (1) PT2326329T (enExample)
RU (1) RU2498804C2 (enExample)
SG (2) SG10202102855RA (enExample)
SI (1) SI2326329T1 (enExample)
SM (2) SMT201700084T1 (enExample)
WO (1) WO2010017163A1 (enExample)
ZA (1) ZA201101662B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) * 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
EP2498751B1 (en) 2009-11-09 2019-04-03 Wyeth LLC Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CN105263499B (zh) * 2013-06-19 2019-11-15 豪夫迈·罗氏有限公司 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合
CA2912816A1 (en) * 2013-06-19 2014-12-24 F. Hoffmann-La Roche Ag Combination of ro5503781 and capecitabine for cancer therapy
WO2015112850A2 (en) * 2014-01-23 2015-07-30 Wenle Xia Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
WO2015123699A1 (en) 2014-02-17 2015-08-20 Children's National Medical Center Method and system for providing recommendation for optimal execution of surgical procedures
KR101964169B1 (ko) * 2014-04-04 2019-04-01 다이호야쿠힌고교 가부시키가이샤 항종양성 백금 착체를 함유하는 항종양제 및 항종양 효과 증강제
WO2017117474A1 (en) * 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
WO2018133838A1 (zh) * 2017-01-22 2018-07-26 江苏恒瑞医药股份有限公司 Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
CN111110681A (zh) * 2018-10-31 2020-05-08 正大天晴药业集团股份有限公司 喹啉衍生物联合卡培他滨在治疗肝癌的用途
WO2021104319A1 (zh) * 2019-11-25 2021-06-03 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐的联用药物组合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081985A1 (en) * 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
WO2007056118A1 (en) * 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
WO2008076143A1 (en) * 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
WO2009042613A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399A (en) 1850-05-28 charles payne
US865A (en) 1838-08-01 Improvement in fire-arms
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (enExample) 1992-12-18 1995-08-21 Hoffmann La Roche
UA41909C2 (uk) 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
CZ303899B6 (cs) 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
ATE278421T1 (de) 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ATE406892T1 (de) 2001-04-06 2008-09-15 Wyeth Corp Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil
PL367267A1 (en) 2001-06-01 2005-02-21 Wyeth Antineoplastic combinations
US20020198137A1 (en) 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US6821988B2 (en) 2001-11-27 2004-11-23 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
SI1509230T1 (sl) 2002-06-05 2007-06-30 Cedars Sinai Medical Center Gefitinib (iressa) za zdravljenje raka
US20060094674A1 (en) 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060006058A (ko) 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
KR20060054412A (ko) * 2003-08-01 2006-05-22 와이어쓰 홀딩스 코포레이션 암 치료 및 억제용 표피 성장인자 수용체 키나제 억제제와세포독성제의 배합물 용도
AU2004267061A1 (en) 2003-08-19 2005-03-03 Wyeth Holdings Corporation Process for the preparation of 4-amino-3-quinolinecarbonitriles
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1670473A1 (en) 2003-09-15 2006-06-21 Wyeth a Corporation of the State of Delaware Substituted quinolines as protein tyrosine kinase enzyme inhibitors
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
EP1756137A4 (en) 2003-11-05 2007-10-31 Univ Texas DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
AR047988A1 (es) 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
EP2439284B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
AU2005263972A1 (en) 2004-07-23 2006-01-26 Astrazeneca Ab Method of predicting the responsiveness of a tumor to erbB receptor drugs
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
TW200626610A (en) 2004-10-13 2006-08-01 Wyeth Corp Analogs of 17-hydroxywortmannin as PI3K inhibitors
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
PL1859793T3 (pl) 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
US8105768B2 (en) 2005-03-09 2012-01-31 Abbott Laboratories Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
AU2006236940A1 (en) 2005-04-14 2006-10-26 Wyeth Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients
WO2006116016A2 (en) 2005-04-21 2006-11-02 The Regents Of The University Of California Molecular determinants of egfr kinase inhibitor response in glioblastoma
US7767668B2 (en) 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
AU2006245421A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
CN101203494A (zh) 2005-05-25 2008-06-18 惠氏公司 合成经取代3-氰基喹啉和其中间物的方法
WO2006127205A2 (en) 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
DE102005053679A1 (de) 2005-06-24 2006-12-28 Bayer Healthcare Ag Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
TW200740427A (en) 2005-07-15 2007-11-01 Wyeth Corp Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
JP5066446B2 (ja) 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
CN101351563A (zh) 2005-10-05 2009-01-21 阿斯利康(英国)有限公司 用于预测或监测病人对于ErbB受体药物的响应的方法
US20110052570A1 (en) 2005-10-26 2011-03-03 Children's Medical Center Corporation Method to prognose response to anti-egfr therapeutics
US20070105887A1 (en) 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate
CA2629249C (en) 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
PL1951274T3 (pl) 2005-11-24 2010-05-31 Aicuris Gmbh & Co Kg Parapoksywirusy w kombinacji z klasycznymi cytotoksycznymi środkami chemioterapeutycznymi jako biochemioterapia do leczenia raka
JP2007145745A (ja) * 2005-11-25 2007-06-14 Osaka Univ 変異型ＥＧＦＲ下流シグナルを抑制するＳｒｃファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
WO2007075794A2 (en) 2005-12-22 2007-07-05 Wyeth Oral formulations comprising tigecycline
WO2007095038A2 (en) 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
JP2009532438A (ja) * 2006-04-07 2009-09-10 ノバルティス アクチエンゲゼルシャフト 白血病の処置のためのピリミジルアミノベンズアミド化合物との組合せでのｃ−Ｓｒｃ阻害剤の使用
TW200806282A (en) 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
TW200808728A (en) 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
WO2008005469A2 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
CA2663599A1 (en) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
JP2010504974A (ja) 2006-09-28 2010-02-18 フォリカ，インコーポレーテッド 新しい毛嚢を生成させ毛髪を成長させる方法、キット、及び組成物
US20090317456A1 (en) 2006-10-13 2009-12-24 Medigene Ag Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
US20100143340A1 (en) 2006-12-13 2010-06-10 Schering Corporation Methods and compositions for treating cancer
EP2104501B1 (en) 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Methods of cancer treatment with igf1r inhibitors
WO2008079346A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
EP2117518A2 (en) 2007-01-12 2009-11-18 Wyeth a Corporation of the State of Delaware Tablet-in-tablet compositions
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
EP2124901B1 (en) 2007-02-01 2017-07-19 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
WO2008121467A2 (en) 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
EP2145188A4 (en) 2007-04-19 2010-06-30 Wellstat Biologics Corp DETECTION OF HER2 / NEU PROTEIN FROM UNISISIONED CIRCULATING CANCER CELLS AND TREATMENT
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
RU2010120674A (ru) 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
AU2008325219A1 (en) 2007-11-05 2009-05-14 Puretech Ventures Methods, kits, and compositions for administering pharmaceutical compounds
EP2247757A2 (en) 2007-12-18 2010-11-10 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
US20100297118A1 (en) 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
WO2009105234A2 (en) 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
WO2009111073A2 (en) 2008-03-06 2009-09-11 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
MX2010010480A (es) 2008-03-25 2010-10-15 Schering Corp Metodos de tratamiento o prevencion del cancer colorrectal.
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2009126662A1 (en) 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
RS58392B1 (sr) 2008-04-18 2019-04-30 Reata Pharmaceuticals Inc Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17
HUE033288T2 (en) 2008-04-18 2017-11-28 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
TW201006474A (en) 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
US20110129456A1 (en) 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
ES2449396T3 (es) 2008-07-22 2014-03-19 Trustees Of Dartmouth College Cianoenonas monocíclicas y métodos de uso de las mismas
EP3175853B1 (en) * 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
WO2010030835A2 (en) 2008-09-11 2010-03-18 Wyeth Llc Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
EP3075864A1 (en) 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2010048477A2 (en) 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
BRPI0921407A2 (pt) 2008-11-07 2019-09-24 Enzo Pharmaceuticals Inc terapia de combinação seletiva de erbb-3 (her3)
WO2010085845A1 (en) 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
AR075239A1 (es) 2009-02-04 2011-03-16 Bipar Sciences Inc Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso
WO2010098627A2 (ko) 2009-02-27 2010-09-02 한올바이오파마주식회사 약제학적 제제
RU2011141121A (ru) 2009-03-11 2013-04-20 Окленд Юнисервисиз Лимитед Пролекарственные формы ингибиторов киназ и их применение в терапии
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
AR076053A1 (es) 2009-04-14 2011-05-18 Schering Corp Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
CA2766067A1 (en) 2009-07-02 2011-01-06 Wyeth Llc 3-cyanoquinoline tablet formulations and uses thereof
KR20110007984A (ko) 2009-07-17 2011-01-25 한올바이오파마주식회사 Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
KR20110007985A (ko) 2009-07-17 2011-01-25 한올바이오파마주식회사 Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
KR101190953B1 (ko) 2009-08-25 2012-10-12 한올바이오파마주식회사 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
WO2011025267A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
WO2011025271A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
CN102665756A (zh) 2009-10-01 2012-09-12 Csl有限公司 费城染色体阳性白血病的治疗方法
EP2498751B1 (en) 2009-11-09 2019-04-03 Wyeth LLC Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
EP3566697B1 (en) 2009-11-09 2024-09-11 Wyeth LLC Tablet formulations of neratinib maleate
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
WO2011069962A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
EP2510121A1 (en) 2009-12-11 2012-10-17 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
JP6126382B2 (ja) 2010-01-13 2017-05-10 ワイス・エルエルシー 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081985A1 (en) * 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
WO2007056118A1 (en) * 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
WO2008076143A1 (en) * 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
WO2009042613A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
European Journal of Cancer, Supplements, 2008, vol. 6, no. 5, pp. 7-14 *

Also Published As

Publication number Publication date
MX2011001318A (es) 2011-03-04
CN115990181A (zh) 2023-04-21
JP2011529968A (ja) 2011-12-15
SMT201700084B (it) 2017-03-08
CN105963313A (zh) 2016-09-28
CN109464445A (zh) 2019-03-15
DK2326329T3 (en) 2017-02-20
CA2730715C (en) 2013-10-01
LT2326329T (lt) 2017-05-25
EP3175853A1 (en) 2017-06-07
NZ590464A (en) 2012-10-26
HUE032958T2 (hu) 2017-11-28
HK1218262A1 (zh) 2017-02-10
CN102202667A (zh) 2011-09-28
CN105147713A (zh) 2015-12-16
US20100113474A1 (en) 2010-05-06
EP2326329B1 (en) 2017-01-11
JP5681108B2 (ja) 2015-03-04
US20140171384A1 (en) 2014-06-19
SG10202102855RA (en) 2021-05-28
ES2614912T3 (es) 2017-06-02
IL210616A (en) 2015-10-29
IL210616A0 (en) 2011-03-31
EP2326329A1 (en) 2011-06-01
KR20110036604A (ko) 2011-04-07
ZA201101662B (en) 2011-11-30
PL3175853T3 (pl) 2024-03-25
SI2326329T1 (sl) 2017-06-30
PT2326329T (pt) 2017-02-14
CA2730715A1 (en) 2010-02-11
HRP20170074T1 (hr) 2017-03-24
US8669273B2 (en) 2014-03-11
ES2968373T3 (es) 2024-05-09
CY1118602T1 (el) 2017-07-12
EP4424375A3 (en) 2024-11-20
KR20140069340A (ko) 2014-06-09
KR101434009B1 (ko) 2014-08-25
BRPI0916694A2 (pt) 2015-11-17
PL2326329T3 (pl) 2017-07-31
AU2009279771A1 (en) 2010-02-11
US9265784B2 (en) 2016-02-23
SMT201700084T1 (it) 2017-03-08
RU2011102797A (ru) 2012-09-10
BRPI0916694B1 (pt) 2021-06-08
CN113209121A (zh) 2021-08-06
EP3175853B1 (en) 2023-11-01
RU2498804C2 (ru) 2013-11-20
SG10201702382RA (en) 2017-05-30
EP4424375A2 (en) 2024-09-04
WO2010017163A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
CA2730715C (en) Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
EP2416774B1 (en) Treatment regimen utilizing neratinib for breast cancer
US20120270896A1 (en) Antineoplastic Combinations Containing HKI-272 and Vinorelbine
HK40113079A (en) Antineoplastic combinations of neratinib and capecitabine
HK1239521A1 (en) Antineoplastic combinations of neratinib and capecitabine
HK1239521B (en) Antineoplastic combinations of neratinib and capecitabine
HK40091861A (en) Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
HK1228780A1 (en) Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
HK1158077A (en) Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
HK40098360A (en) Treatment regimen utilizing neratinib for breast cancer
AU2013202963B2 (en) Antineoplastic Combinations Containing HKI-272 and Vinorelbine
HK1167313B (en) Treatment regimen utilizing neratinib for breast cancer
HK1223027B (en) Treatment regimen utilizing neratinib for breast cancer
AU2016202225A1 (en) Antineoplastic combinations containing HKI-272 and vinorelbine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)